CD44 expression in neuroblastoma and related tumors

被引:9
|
作者
Comito, MA
Savell, VH
Cohen, MB
机构
[1] UNIV IOWA HOSP & CLIN, DEPT PEDIAT, IOWA CITY, IA 52242 USA
[2] UNIV IOWA HOSP & CLIN, DEPT PATHOL, IOWA CITY, IA 52242 USA
[3] UNIV IOWA HOSP & CLIN, DEPT UROL, IOWA CITY, IA 52242 USA
[4] VET AFFAIRS MED CTR, IOWA CITY, IA 52242 USA
关键词
neuroblastoma; CD44; N-myc; survival; cellular adhesion molecules;
D O I
10.1097/00043426-199707000-00005
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: A retrospective study was conducted to investigate the relationship between CD44 expression in neuroblastoma and related tumors and other known prognostic indicators. Materials and Methods: Immunostaining of CD44 was done on surgical specimens of 55 cases (42 patients) of neuroblastoma (NB) and ganglioneuroblastoma (GNB) and nine cases of ganglioneuroma. The percentage of positive tumor cells was scored semiquantitatively (0-4+) by two observers. CD44 expression was then correlated with survival, age, stage, and N-myc amplification. Results: Fifty-seven percent of the patients with NE or GNB had heterogeneous positive staining (2-1+) on their diagnostic specimens. Twenty-four percent of the patients had no staining for CD44, and 19% had 1+ staining. In the 17 cases with N-myc analysis, an inverse relationship was demonstrated between N-myc and CD44 expression by univariate analysis. Lack of expression of CD44 was highly associated with poor survival (p = 0.0002). When assessing the joint effects of age, stage, and CD44 in multivariate analysis, the effect of CD44 remains significant (p = 0.028) and appears to be independent of age and stage. Conclusion: Our data suggest a relationship between CD44 and N-myc amplification. Absence or low expression of CD44 correlates with poor survival and may be a biologic marker of tumor aggressiveness. CD44 appears to be an independent prognostic marker and deserves continued investigation in prospective studies of neuroblastoma.
引用
收藏
页码:292 / 296
页数:5
相关论文
共 50 条
  • [1] CD44 EXPRESSION AND MODULATION ON HUMAN NEUROBLASTOMA TUMORS AND CELL-LINES
    GROSS, N
    BECK, D
    BERETTA, C
    JACKSON, D
    PERRUISSEAU, G
    EUROPEAN JOURNAL OF CANCER, 1995, 31A (04) : 471 - 475
  • [2] CD44, A NEW PROGNOSTIC MARKER FOR NEUROBLASTOMA
    COMBARET, V
    LASSET, C
    BOUVIER, R
    FRAPPAZ, D
    THIESSE, P
    REBILLARD, AC
    PHILIP, T
    FAVROT, MC
    BULLETIN DU CANCER, 1995, 82 (02) : 131 - 136
  • [3] Response to "High CD44 expression is not a prognosis marker in patients with high-risk neuroblastoma"
    Vega, Francisco M.
    Colmenero-Repiso, Ana
    Gomez-Munoz, Maria A.
    Rodriguez-Prieto, Ismael
    Aguilar-Morante, Diana
    Ramirez, Gema
    Marquez, Catalina
    Cabello, Rosa
    Pardal, Ricardo
    EBIOMEDICINE, 2020, 53
  • [4] MYCN-related suppression of functional CD44 expression enhances tumorigenic properties of human neuroblastoma cells
    Gross, N
    Bourloud, KB
    Brognara, CB
    EXPERIMENTAL CELL RESEARCH, 2000, 260 (02) : 396 - 403
  • [5] Clinical relevance of TRKA expression on neuroblastoma: Comparison with N-MYC amplification and CD44 expression
    Combaret, V
    Gross, N
    Lasset, C
    Balmas, K
    Bouvier, R
    Frappaz, D
    BerettaBrognara, C
    Philip, T
    Favrot, MC
    Coll, JL
    BRITISH JOURNAL OF CANCER, 1997, 75 (08) : 1151 - 1155
  • [6] Expression of CD44 is associated with aggressiveness in seminomas
    Labropoulou, Vasiliki T.
    Manou, Dimitra
    Ravazoula, Panagiota
    Alzahrani, Fatimah Mohammed
    Kalofonos, Haralabos P.
    Theocharis, Achilleas D.
    MOLECULAR BIOLOGY REPORTS, 2024, 51 (01)
  • [7] Expression of CD44 is associated with a metastatic pattern of human neuroblastoma cells in a SCID mouse xenograft model
    Valentiner, Ursula
    Valentiner, Fried-Ulrich
    Schumacher, Udo
    TUMOR BIOLOGY, 2008, 29 (03) : 152 - 160
  • [8] Correlation of MYCN amplification, trk-A and CD44 expression with clinical stage in 250 patients with neuroblastoma
    Kramer, K
    Cheung, NKV
    Gerald, WL
    LaQuaglia, M
    Kushner, BH
    LeClerc, JM
    LeSauter, L
    Saragovi, HU
    EUROPEAN JOURNAL OF CANCER, 1997, 33 (12) : 2098 - 2100
  • [9] CD44 expression in benign and malignant nevomelanocytic lesions
    Leigh, CJ
    Palechek, PL
    Knutson, JR
    McCarthy, JB
    Cohen, MB
    Argenyi, ZB
    HUMAN PATHOLOGY, 1996, 27 (12) : 1288 - 1294
  • [10] Prognostic Impact of CD44 Expression in Patients With Myxofibrosarcoma
    Tsuchie, Hiroyuki
    Emori, Makoto
    Miyakoshi, Naohisa
    Nagasawa, Hiroyuki
    Okada, Kyoji
    Nanjyo, Hiroshi
    Murahashi, Yasutaka
    Mizushima, Emi
    Shimizu, Junya
    Yamashita, Toshihiko
    Shimada, Yoichi
    IN VIVO, 2019, 33 (06): : 2095 - 2102